Advances in dry eye disease treatment

Abstract

Purpose of review: The prevalence and burden of dry eye disease continues to grow at a rapid pace, creating an increased need for new therapies. In a sector once limited to only a handful of treatments, clinicians now have multiple options available for patients who fail traditional therapies. This review summarizes the various treatment options available to clinicians treating complex dry eye disease patients.

Recent findings: As we better understand the multifactorial mechanisms leading to dry eye disease, treatments increasingly focus on the amelioration of the underlying deficiencies and inflammation, rather than on transient symptomatic relief alone. Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures seek to treat meibomian gland dysfunction, with one new device stimulating tear production through utilizing the nasolacrimal reflex pathway.

Summary: Clinicians have more options at their disposal in the treatment of dry eye disease than ever before, including topical medications and devices.

Conflict of interest statement

Conflicts of interest

MMG: Celularity (consultant); Glaxo-Smith Kline (consultant); PRN Omega (personal financial interest)

ECO, MH: None

Figures

Figure 1:

Application of Intense pulsed light (IPL)

Figure 2:

Thermal pulsation system

Figure 3:

MiBo ThermoFlo application device

Figure 4:

TearCare iLid device

Figure 5:

Intranasal Tear Neurostimulator